Pharmacovigilance is something that has no borders and in July this year, some key regulations were passed which will have a profound effect conceptually and technically on those who are working with pharma products which are commercialised in the EU. However, those working in risk management in North America will also need a clear understanding of the impact that these regultaions are likely to have. In this short interiew on pharmacovigilance and pharma regulatory compliance, Joanna Haas, Founding Partner at Haas and Partners LLC in Boston, explains the processes and procedures that will take effect due to the new direction in pharmacovigilance and risk management.
|
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |